Should a patient with HBV-DNA over 10,000 IU/ml receive antiviral therapy?
Evidence shows that patients with CHB and HBV-DNA over 10,000 IU/ml should receive antiviral therapy due to its efficacy in reducing viral load and lowering the risk of liver disease complications.
Authors
- Tripdatabase
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-18
- DOI
- https://doi.org/10.5281/zenodo.24341145
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00